Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

EGFR exon 20 insertions is one tough cookie to crack! Was reading about Astellas' P3 trial for NSCLC EGFR mutations which just got halted after review by the data monitoring committee. You'd think that EGFR mutations would include EGFR exon 20 insertions but not so in this trial. Here's part of the Inclusion criteria

Subject has an EGFR activating mutation (exon 19 deletion or exon 21 L858R), with or without T790M mutation, by local or central testing on examination of a NSCLC FFPE specimen (archival or fresh biopsy). Subjects harboring both exon 19 deletion and exon 21 L858R mutations are not eligible.

And yet the Poziotinib trial is going after the EGFR exon 20 insertions patients. I suspect that if Poziotinib succeeds with EGFR exon 20 insertions it won't have any competition. I also wonder how it would do w other EGFR mutations? But OK, one step at a time.